Gritstone Bio: Q1 Earnings Insights
Gritstone Bio (NASDAQ:GRTS) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:05 PM. Here’s what…
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell
• Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter.
• Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
Moderna, Merck’s Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial
Moderna, Inc (NASDAQ:MRNA) and Merck & Company, Inc’s (NYSE:MRK) cancer vaccine exhibited positive results against relapse for melanoma patients, results from a midstage…
Benzinga’s Top Ratings Upgrades, Downgrades For March 28, 2023
Upgrades For Coherus BioSciences Inc (NASDAQ:CHRS), UBS upgraded the previous rating of Neutral to Buy. Coherus BioSciences earned…
Gritstone Bio Cash, Cash Equivalents, Marketable Securities And Restricted Cash Were $185.2M As Of December 31, 2022, Compared To $223.5M As Of December 31, 2021
Full Year 2022 Financial Results
Cash, cash equivalents, marketable securities and restricted cash were $185.2 million as of December 31, 2022, compared to $223.5 million as of December 31,
Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Gritstone bio And The National Cancer Institute Establish Clinical Trial Agreement To Evaluate A Neoantigen Cell Therapy-Vaccine Combination
Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). Gritstone will provide the
Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket
Gainers
Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.